

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated August 8, 2013,
1. Liberty Hospital Nuclear Medicine Department	3. License number 24-16178-01 is amended in its entirety to read as follows:
2. 2525 Glenn W. Hendren Drive Liberty, MO 64069-1002	4. Expiration date April 30, 2021
	5. Docket No. 030-10532 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Palladium-103, permitted by 10 CFR 35.400	D. Sealed Sources (Theragenics Corporation Model TheraSeed 200)	D. 1 curie
E. Depleted Uranium	E. Stainless steel covered metal	E. 4 shields, not to exceed 12 kilograms each

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - E. Shielding in ADAC Laboratories MCD-AC attenuation correction system.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-16178-01

Docket or Reference Number
030-10532

Amendment No. 43

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 2521 Glenn W. Hendren Drive, Liberty, Missouri and 2525 Glenn W. Hendren Drive, Liberty, Missouri.
11. The Radiation Safety Officer for this license is Joseph Caresio, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Robert C. Newth, M.D.	10 CFR 35.100, 35.200, and 35.300.
Robert A. MacNaughton, II, M.D.	10 CFR 35.100, 35.200, and 35.300.
Richard A. Morrison, M.D.	10 CFR 35.400.
Gordon D. Stillie, M.D.	10 CFR 35.400.
Scott C. Cozad, M.D.	10 CFR 35.400.
John I. Halloran, M.D.	10 CFR 35.100, 35.200, and 35.300.
Timothy G. Raveill, M.D.	10 CFR 35.100 and 35.200.
Randall C. Newth, M.D.	10 CFR 35.100 and 35.200.
Michael P. Green, D.O.	10 CFR 35.100 and 35.200.
Joseph Caresio, M.D.	10 CFR 35.100 and 35.200.
John Brian Pope, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Arnold Pollak, M.D.	10 CFR 35.200.
Dwarakraj Soundarraj, M.D.	10 CFR 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-16178-01Docket or Reference Number
030-10532**Amendment No. 43**

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 27, 2010; and
- B. Facsimiles dated March 16, 2011 and March 17, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date OCT 21 2013

By

Toye L. Simmons
Materials Licensing Branch
Region III